Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019621 (Langerhans cell histiocytosis)
 3,250 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Skeleton and soft tissue findings in systemic dermatoses sometimes allow early differentiation between diseases affecting the skin only and those involving other organs too. Rarely, ossious alterations can be detected even before any cutaneous manifestations have shown up. Apart from a tabular survey, we refer in detail to the frequency as well as the diagnostic value of ossious and soft tissue findings in dermatomyositis, lupus erythematosus, systemic sclerosis, psoriasis, Reiter's disease, sarcoidosis, neurofibromatosis (Recklinghausen's disease), histiocytosis X, and pretibial myxedema. Particular attention is paid to the problems of differential diagnosis with special regard to rheumatoid arthritis.
 ...
PMID:[Roentgenmorphologic findings in systemic dermatoses]. 329 34

There have been concerns that growth hormone (GH) therapy may be associated with an increased risk of cancer. Although data are limited and conflicting, one recent report on cancer risk in individuals with no cancer history or risk factors for cancer who were treated with pituitary GH demonstrated a small increased risk of colon cancer and deaths from colon cancer and Hodgkin disease. The data from cancer survivors have consistently shown no increased risk of recurrence of the primary tumor in survivors of all tumor types who are treated with GH. One recent study did show a small increased risk of second solid tumors in survivors previously treated with GH. Limited data suggest that GH therapy is not associated with excess cancer risk in individuals with Langerhans cell histiocytosis and neurofibromatosis type 1. Overall, the clinical data are reassuring, but continued surveillance is mandatory.
 ...
PMID:Growth hormone treatment: cancer risk. 1553 96

Juvenile xanthogranuloma (JXG) is a benign histiocytic skin disorder mainly encountered during infancy and childhood. Although with multiple potential localizations, less than 1% of the cases exhibit ocular manifestations. Some of these might lead to serious complications, specifically, secondary glaucoma that can result in severe and blinding eye disease. The aim of the present case report was to demonstrate typical clinical features, emphasize the difficulties attributed when managing these patients and literature review. We present the case of 4 months old female baby with spontaneous hyphema and secondary unilateral glaucoma due to ocular JXG. The natural history and treatment of the condition were extremely difficult to handle due to multiple opinions in histopathology related to other severe conditions that resembled with the lesions detected in this case: myelomonocytic leukemia and Langerhans cell histiocytosis. Although a minority of patients with JXG have ocular involvement, recognition of this condition is important because a treatment delay can lead to serious complications, such as glaucoma and spontaneous hyphema, as in our case. A thorough differential diagnosis represents the key to a proper management plan in these patients, both on short and long term. "Triple disease" defined as JXG plus neurofibromatosis type 1 (NF-1) and juvenile chronic myelogenous leukemia (JCML) has been reported, but it was not confirmed in our patient.
 ...
PMID:Iris juvenile xanthogranuloma in an infant - spontaneous hyphema and secondary glaucoma. 2945 Apr 3